ALLIANCE A031803

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Open

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NCT#04164082

A031803 is reopened to accrual with implementation of Update 8, effective April 18, 2023.